We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Guidelines Issued on Appropriate Use of Platelet Transfusion

By LabMedica International staff writers
Posted on 23 Nov 2014
Platelet transfusions are administered to prevent or treat bleeding in patients with quantitative or qualitative platelet disorders and new guidelines have been issued that specify clinical situations in which platelet transfusion is recommended in adult patients.

The developed guidelines address several common clinical situations and attempt to identify a platelet count threshold below which platelet transfusion may improve hemostasis and above which platelet transfusion is unlikely to benefit the patient.

Led by hematologists at the Brigham and Women's Hospital (Boston MA, USA) a team of scientists performed a systematic review of randomized, clinical trials and observational studies that reported clinical outcomes on patients receiving prophylactic or therapeutic platelet transfusions. More...
A literature search from 1900 to September 2014 with no language restrictions was done. Examined outcomes included all-cause mortality, bleeding-related mortality, bleeding, and number of platelet units transfused. An expert panel reviewed the data and developed recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

The AABB (formerly, the American Association of Blood Banks, Bethesda, MD, USA) recommends prophylactic platelet transfusion to reduce the risk for spontaneous bleeding in hospitalized adult patients with therapy-induced hypoproliferative thrombocytopenia and a platelet count of 10 × 109 cells/L. There is weaker evidence to suggest that prophylactic platelet transfusion should be administered in patients having elective central venous catheter placement with a platelet count of less than 20 × 109 cells/L or patients having elective diagnostic lumbar puncture or major elective non-neuraxial surgery with a platelet count less than 50 × 109 cells/L.

The team recommended against routine prophylactic platelet transfusion in patients who are non-thrombocytopenic and have cardiac surgery with cardiopulmonary bypass but suggests, without recommending, that those with perioperative bleeding and thrombocytopenia or platelet dysfunction may benefit from transfusion. They concluded that the ideal approach to platelet transfusion would be to administer sufficient platelets to optimize patient outcomes while avoiding unnecessary transfusions with their attendant risks and costs. The recommendations in their guideline reflect the AABB's current thinking on how platelet transfusions should be used in various clinical settings. The study was published on November 11, 2014, in the journal Annals of Internal Medicine.

Related Links:

Brigham and Women's Hospital
AABB 



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Thyroid Test
Anti-Thyroid EIA Test
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.